5

General Information


DRACP ID  DRACP05998

Peptide Name   5

Sequence  FETLRGDLRILSILRⓍQNLⓍKELQD

Sequence Length  25

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic (Derived from chromogranin A)

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Stapled Peptides αvβ6/αvβ8 inhibitor



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  αvβ6, αvβ8

Affinity  αvβ6: Ki=0.6 ± 0.1 nM; αvβ8: Ki=3.2 ± 1.2 nM

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Cyclic (Stapled)

Disulfide/Other Bond  Stapled: Ⓧ(16) and Ⓧ (20) are cross-linked by triazole bridge stapling

N-terminal Modification  Acetylation

C-terminal Modification  Amidation

Other Modification  Ⓧ(16)=Propargylglycine; Ⓧ(20)=Azidolysine

Chiral  L



Physicochemical Information


Formula  C122H204N36O35

Absent amino acids  ACHMPVWY

Common amino acids  L

Mass  316346

Pl  6.63

Basic residues  4

Acidic residues  4

Hydrophobic residues  9

Net charge  0

Boman Index  -6178

Hydrophobicity  -36.8

Aliphatic Index  124.8

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 36594095

Title  A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins

Doi 10.7150/ijbs.76148

Year  2023

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.